SCHEMBL2182291

SCHEMBL2182291

Cn1c(=O)c2nc(NCCNCCO)nnc2n(C2CCCC2)c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.36
CDK1 P06493 2/20 0.34
CCNE1 P24864 7/20 0.34
CDK2 P24941 7/20 0.34
CCND1 P24385 6/20 0.34
CDK6 Q00534 6/20 0.34
CCNT1 O60563 2/20 0.34
CDK9 P50750 2/20 0.34
RB1 P06400 1/20 0.34
CDK4 P11802 1/20 0.34
OPRM1 P35372 1/20 0.33
OPRK1 P41145 1/20 0.33
OGFRL1 Q5TC84 1/20 0.33
TYRO3 Q06418 1/20 0.33
MERTK Q12866 1/20 0.33
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
JAK3 P52333 1/20 0.32
PRKDC P78527 2/20 0.32
CSF1R P07333 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2183096 0.95 ADORA2A (0.36) ADORA2ACDK1CCNE1CDK2CCND1
SCHEMBL2180415 0.88 CYP2D6 (0.37) ADORA2ACCNE1CDK2CDK6CCNT1
SCHEMBL2182366 0.87 ADORA2A (0.39) ADORA2ACCNE1CDK2CCND1CDK6
SCHEMBL2184354 0.86 CCND1 (0.35) ADORA2ACCNE1CDK2CCND1CDK6
SCHEMBL2182066 0.85 ADORA2A (0.36) ADORA2AOPRM1OPRK1OGFRL1TYRO3
SCHEMBL2184389 0.85 ADORA2A (0.38) ADORA2ACCNE1CDK2CCND1CDK6
SCHEMBL2182414 0.85 ADORA2A (0.39) ADORA2ACCNE1CDK2CCND1CDK6
SCHEMBL2181649 0.83 KDM1A (0.37) ADORA2APRKDCCSF1RTTKPIK3CA
SCHEMBL2182670 0.83 CYP2C19 (0.42) JAK2KDM4EGAAMAPTKMT2A
SCHEMBL2180585 0.83 CYP2D6 (0.42) ADORA2ACCNE1CDK2CCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181524-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2023-06-15 US disclosed
EP-4129282-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2023-02-08 EP disclosed
US-20110166144-A1 Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181524-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF TCF4, TCF7L2, CTNNB1 ADORA2A 2201/4885CDK1 1687/4885CCNE1 1182/4885
US-20110166144-A1 Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same DPYD, TYMP, DHFR ADORA2A 836/4885CDK1 952/4885CCNE1 892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.